The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability
Open accessAbstract
The relationship of relapses to long-term disability in multiple sclerosis is uncertain. Relapse reduction is a common therapeutic target but clinical trials have shown dissociation between relapse suppression and disability accumulation. We investigated relationships between relapses and disability progression for outcomes of requiring assistance to walk, being bedridden and dying from multiple sclerosis [Disability Status Scale 6, 8, 10] by analysing 28 000 patient-years of evolution in 806-bout onset patients from the London Ontario natural history cohort. Having previously shown no effect of relapse frequency among progressive multiple sclerosis subtypes, here we examined these measures in the pre-progressive or relapsing-remitting phase. Survival was compared among groups stratified by (i) early relapses--number of attacks during the first 2 years of multiple sclerosis; (ii) length of first inter-attack interval; (iii) interval between onset and Disability Status Scale 3 (moderate disability); (iv) number of attacks from the third year of disease up to onset of progression; and (v) during the entire relapsing-remitting phase. Early clinical features can predict hard disability outcomes. Frequent relapses in the first 2 years and shorter first inter-attack intervals predicted shorter times to reach hard disability endpoints. Attack frequencies, in the first 2 years, of 1 versus >or=3, gave differences of 7.6, 12.8 and 20.3 years in times from disease onset to Disability Status Scale 6, 8 and 10, respectively. Time to Disability Status Scale 3 highly and independently predicted time to Disability Status Scale 6, 8 and 10. In contrast, neither total number of relapsing-remitting phase attacks nor of relapses experienced during the relapsing-remitting phase after the second year up to onset of progression showed a deleterious effect on times from disease onset, from progression onset and from Disability Status Scale 3 to these hard endpoints. The failure of a regulatory mechanism tied to neurodegeneration is suggested. Relapse frequency beyond Year 2 does not appear to predict the key outcome of secondary progression or times to Disability Status Scale 6, 8 or 10, highlighting two distinct disease phases related to late outcome. These appear to be separated by a watershed within the relapsing-remitting phase, just a few years after clinical onset. Higher early relapse frequencies and shorter first inter-attack intervals herald more rapid deterioration via interaction with the neurodegeneration characterizing secondary progression. They increase the probability of its occurrence, its latency and influence--to a lesser degree--its slope. The prevention or delay of the progressive phase of the disease is implicated as a key therapeutic target in relapsing-remitting patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Self-citationCox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Breslow, N., Cox, D. R., & Oakes, D. (1985) · Biometrics · doi:10.2307/2530888 · Cited by 4,333
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Self-citationPaty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
The clinical course of neuromyelitis optica (Devic’s syndrome)
Wingerchuk, D. M., Hogancamp, W. F., O’Brien, P. C., & Weinshenker, B. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1107 · Cited by 1,822
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724 · cited 2×
“Biological mechanisms leading to acute attacks probably differ from those responsible for unremitting disability (Bjartmar et al., 2001; DeLuca et al., 2006; Trapp and Nave, 2008).”
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Self-citationThe relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
Self-citationConfavreux, C. (2003) · Brain · doi:10.1093/brain/awg081 · Cited by 996
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 916
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.6.1419 · Cited by 602
Self-citationCONFAVREUX, C., AIMARD, G., & DEVIC, M. (1980) · Brain · doi:10.1093/brain/103.2.281 · Cited by 494
Multiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-up
(2008) · Archives of Neurology · doi:10.1001/archneur.65.6.727 · Cited by 476
Kremenchutzky, M., Rice, G. P. A., Baskerville, J., Wingerchuk, D. M., & Ebers, G. C. (2006) · Brain · doi:10.1093/brain/awh721 · Cited by 447
Self-citationMultiple sclerosis in the Japanese population
Kira, J.-I. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00308-9 · Cited by 419
Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
Rice, G. P. A., Filippi, M., Comi, G., & for the Cladribine Clinical Study Group and for the Cladribine MRI Study Group* (2000) · Neurology · doi:10.1212/wnl.54.5.1145 · Cited by 325
Self-citationA New Scale for Evaluating Disability in Multiple Sclerosis
Kurtzke, J. F. (1955) · Neurology · doi:10.1212/wnl.5.8.580 · Cited by 297
Axonal loss in normal-appearing white matter in a patient with acute MS
Bjartmar, C., Kinkel, R. P., Kidd, G., Rudick, R. A., & Trapp, B. D. (2001) · Neurology · doi:10.1212/wnl.57.7.1248 · Cited by 281
The contribution of demyelination to axonal loss in multiple sclerosis
DeLuca, G. C. (2006) · Brain · doi:10.1093/brain/awl074 · Cited by 231
Eriksson, M., Andersen, O., & Runmarker, B. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms914oa · Cited by 221
The treatment of chronic progressive multiple sclerosis with cladribine.
Beutler, E., Sipe, J. C., Romine, J. S., Koziol, J. A., McMillan, R., & Zyroff, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1716 · Cited by 208
The natural history of multiple sclerosis: a geographically based study
Kremenchutzky, M., Cottrell, D., Rice, G., Hader, W., Baskerville, J., Koopman, W., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.10.1941 · Cited by 186
Self-citationMyhr, K., Riise, T., Vedeler, C. A., Nortvedt, M. W., Grønning, M., Midgard, R., & Nyland, H. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700110 · Cited by 184
Survival and predictors of disability in Turkish MS patients
Kantarci, O., Siva, A., Eraksoy, M., Karabudak, R., Sütlaş, N., Ağaoğlu, J., Turan, F., Özmenoğlu, M., Toğrul, E., Demirkiran, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.3.765 · Cited by 168
The Natural History of Multiple Sclerosis
Weinshenker, B. G., & Ebers, G. C. (1987) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100026573 · Cited by 143
Self-citationPHADKE, J. G. (1990) · Brain · doi:10.1093/brain/113.6.1597 · Cited by 134
Patzold, U., & Pocklington, P. R. (1982) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1982.tb03084.x · Cited by 121
Goodkin, D. E. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460093019 · Cited by 90
Meinl, E., Krumbholz, M., Derfuss, T. J., Junker, A., & Hohlfeld, R. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.06.032 · Cited by 87
Clinical studies on multiple sclerosis
Broman, T., Andersen, O., & Bergmann, L. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb00745.x · Cited by 84
Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada
Hader, W. J., Elliot, M., & Ebers, G. C. (1988) · Neurology · doi:10.1212/wnl.38.4.617 · Cited by 81
Self-citationThe course of multiple sclerosis in 73 cases with computer-designed curves.
Fog, T., & Linnemann, F. (1970) · PubMed · Cited by 73
Cyclophosphamide and plasma exchange in multiple sclerosis
Noseworthy, J. H., Vandervoort, M. K., Mf, P., Ebers, G. C., Shumak, K. H., Seland, T. P., Roberts, R. A., Yetisir, E., Gent, M., & Taylor, D. W. (1991) · The Lancet · doi:10.1016/0140-6736(91)93226-y · Cited by 47
Self-citationKordower (1999) · doi:10.1002/1531-8249(199909)46:3
Cited by
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628
Jakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H., Zipp, F., & Weinstock-Guttman, B. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01473-3 · Cited by 597
Metadata
- Authors
- Scalfari, A., Neuhaus, A., Degenhardt, A., Rice, G. P., Muraro, P. A., Daumer, M., & Ebers, G. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-06-09
- Volume
- 133
- Issue
- 7
- Pages
- 1914-1929
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2143953700
- Cited by
- 711
- References
- 49
- FWCI
- 29.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.